NCT03682120: A reported trial by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03682120 |
|---|---|
| Title | A Phase II Study in Healthy Adults 18-64 Years Old to Assess the Safety, Reactogenicity and Immunogenicity of a Seqirus A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without MF59(R) Adjuvant |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 2, 2018 |
| Completion date | April 30, 2020 |
| Required reporting date | April 30, 2021, midnight |
| Actual reporting date | April 22, 2021 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | None |